REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/26/2026
Back to search
Official data from USPTO
ANOCCA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ANOCCA
ST13
US500000079275199Class
1, 5, 9, 10, 42, 44
Filing
79275199
Registration
6253444
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
01/27/2026
Trademark type
Word
Nice classes
1, 5, 9, 10, 42, 44
Filing date
07/16/2019
Registration date
01/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/26/2021
Last transaction
01/27/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
SE
Examiner
ADORNO SANTOS, LUZ M.
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Anocca AB
Representatives
Mark S. Kaufman Kaufman & Kahn, LLP
Technical classification
Nice Classes
Class 1Class 5Class 9Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biochemicalsfor in vitro genetic engineering use; biochemicalsfor ex vivo genetic engineering use; biochemicalsprecursors for in vitro genetic engineering use; biochemicalsprecursors for ex vivo genetic engineering use; biological preparations for use in cell cultures other than for medical or veterinary use; biological preparationsfor in vitro genetic engineering use; biological preparationsfor ex vivo genetic engineering use; biological preparationsprecursors for in vitro genetic engineering use; biological preparationsprecursors for ex vivo genetic engineering use; biological preparations for use in industry and science in the diagnosis of disease and manufacture of cell-based therapies and vaccines; biological preparationsother than for medical or veterinary purposes; biological tissue culturesother than for medical or veterinary purposes; biological preparations other than for medical use; biological preparations for use in industry and science; chemical reagents for molecular biologyother than for medical or veterinary use; chemical reagents for use in biotechnologyother than for medical or veterinary use; chemical reagentsfor in vitro genetic engineering use; chemical reagentsfor ex vivo genetic engineering use; chemical reagentsprecursors for in vitro genetic engineering use; chemical reagentsprecursors for ex vivo genetic engineering use; diagnostic preparationsother than for medical or veterinary purposes; diagnostic preparationsfor in vitro genetic engineering use; diagnostic preparationsfor ex vivo genetic engineering use; diagnostic preparationsprecursors for in vitro genetic engineering use; diagnostic preparationsprecursors for ex vivo genetic engineering use; immunoassay reagentsother than for medical use; immunoassay reagentsfor in vitro genetic engineering use; immunoassay reagentsfor ex vivo genetic engineering use; immunoassay reagentsprecursors for in vitro genetic engineering use; immunoassay reagentsprecursors for ex vivo genetic engineering use; immunoassays based on polypeptides for determining immunological profileother than for medical use; reagents for use in immunoserology for non-medical purposes; reagentsfor in vitro genetic engineering use; reagentsfor ex vivo genetic engineering use; reagentsprecursors for in vitro genetic engineering use; reagentsprecursors for ex vivo genetic engineering use
Class 5
Biological preparations for veterinary and medical purposesfor cell therapy; biological preparations for medical purposes in the field of ex vivo gene engineeringfor cell therapy; biological preparations for treatment using cellular therapeuticsfor cell therapy; biological preparations for treatment using cellular therapy; biological preparations for medical use for cell therapy; biological preparations for treatment of diseases using cellsfor cell therapy; biological preparations for medical purposes for the treatment of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; biological preparations for treatment of cancer; biological tissue cultures for medical purposes; cellular function activating agents for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic preparations and substances for veterinary and medical purposes; diagnostic preparation for medical use; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical purposes; immunoassay reagents for medical use; immunomodulators; immunostimulants; in vitro diagnostic preparation for medical use; mixed biological preparations for medical purposes for the treatment of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; personalized antigens for medical diagnostic use; personalized tumour antigens for medical diagnostic use; personalized tumour vaccines; personalized vaccines; pharmaceutical compositions for the treatment of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; pharmaceutical compositions and substances with anti-inflammatory properties for the treatment of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; pharmaceutical compositions for the prevention of autoimmune conditions; pharmaceutical compositions for the prevention of autoimmune diseases; pharmaceutical compositions for the prevention of autoimmune disorders; pharmaceutical compositions for the prevention of inflammatory conditions; pharmaceutical compositions for the prevention of inflammatory disorders; pharmaceutical compositions for the prevention of inflammatory diseases; pharmaceutical compositions for the prevention of oncological conditions; pharmaceutical compositions for the prevention of oncological disorders; pharmaceutical compositions for the prevention of oncological diseases; pharmaceutical compositions for the prevention of tumours; pharmaceutical compositions for the treatment of autoimmune conditions; pharmaceutical compositions for the treatment of autoimmune diseases; pharmaceutical compositions for the treatment of autoimmune disorders; pharmaceutical compositions for the treatment of inflammatory conditions; pharmaceutical compositions for the treatment of inflammatory disorders; pharmaceutical compositions for the treatment of inflammatory diseases; pharmaceutical compositions for the treatment of oncological conditions; pharmaceutical compositions for the treatment of oncological diseases; pharmaceutical compositions for the treatment of oncological disorders; pharmaceutical compositions for the treatment of tumours; pharmaceutical preparations for the treatment of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; pharmaceutical preparations and substances for the treatment and prevention of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances with anti-inflammatory properties for the treatment of autoimmune diseasebiologic drug rejection and allergy; pharmaceutical preparations for activating cellular function for the treatment of cancerinfectious diseaseautoimmune disease and allergy; pharmaceutical preparations for human use in the treatment and prevention of cancerinfectious diseaseallergy and autoimmune disease; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for medical purposesfor the treatment of cancerinfectious diseaseallergyautoimmune disease and biologic drug rejection; pharmaceutical preparations for prevention of tumours; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of autoimmune conditions; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of inflammatory conditions; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of oncological conditions; pharmaceutical preparations for the prevention of oncological disorders; pharmaceutical preparations for the prevention of oncological diseases; pharmaceutical preparations for the treatment of autoimmune conditions; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of inflammatory conditions; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of oncological conditions; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations for the treatment of oncological disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of digestive system disorders; pharmaceutical preparations for treatment of tumours; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; preparations for detecting genetic predispositions for medical purposes; prophylactic vaccines; reagents for use in medical genetic testing; medical diagnostic reagents in the nature of tumour antigens for use in the detection of cancer; tumour vaccines; vaccines; vaccines for human use; viral vaccines
Class 9
Immunostaining instruments for scientific purposes
Class 10
Apparatus for the diagnosis of autoimmune conditions; medical apparatus for treatment using ex vivo genetic engineeringapparatus for use in cell therapy; medical apparatus for cellular therapeutics; medical apparatus for cell therapy; medical apparatus for cellular therapy; apparatus for treatment of diseases using cellsapparatus for use in cell therapy; apparatus for the diagnosis of autoimmune diseases; apparatus for the diagnosis of autoimmune disorders; apparatus for the diagnosis of inflammatory conditions; apparatus for the diagnosis of inflammatory diseases; apparatus for the diagnosis of inflammatory disorders; apparatus for the diagnosis of oncological conditions; apparatus for the diagnosis of oncological diseases; apparatus for the diagnosis of oncological disorders; apparatus for tumour diagnosis; diagnostic apparatus for medical purposes for testing antigen targets in cancerinfectious diseaseallergyautoimmune disease and biologic drug rejectionin providing targeting immune receptors for antigen targets in said diseases; diagnostic imaging apparatus for medical use; diagnostic instruments for medical useapparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing; medical diagnostic testing apparatus for use in immunoassay procedure; genetic testing apparatus for medical purposes
Class 42
Analysis in the field of molecular biology; analysis of human serum for medical research; analysis of human tissues for medical research; biochemical research and analysis; biochemical research in the field of ex vivo gene engineering; biochemical research in the field of cellular therapeutics; biochemical research in the field of cell therapy; biochemical research in the field of cellular therapy; biochemical research in the field of treatment of diseases using cells; biological laboratory services for scientific research purposes; biological research; biological research and analysis; biological research laboratory services; biological research services; biological researchclinical research and medical research; biomedical research services; biotechnology research; blood analysis services for scientific research purposes; cell separation research services; clinical trials for others; conducting clinical trials for others; conducting clinical trials for others for pharmaceutical products; conducting clinical trials for others in the field of autoimmune disease therapy; conducting clinical trials for others in the field of cancer therapy; conducting clinical trials for others in the field of gene therapy; contract research servicesmedicalpharmaceuticalscientific research for others relating to molecular sciences; DNA screening for scientific research purposes; genetic engineering servicesscientific research in the field of genetics and genetic engineering; genetic engineering servicesscientific research in the field of genetics and genetic engineering relating to plants; genetic research; genetic testing for scientific research purposes; scientific laboratory services; laboratory research in the field of immunobiology; laboratory research in the field of gene expression; laboratory research services relating to pharmaceuticals; scientific laboratory testing services; laboratory services relating to the production of monoclonal antibodies; medical laboratory testing services; medical and pharmacological research services; medical laboratory services; medical research; medical research laboratory services; medical research services; pharmaceutical research and development; pharmaceutical research and development services; pharmaceutical research services; scientific laboratory servicespreparation of biological samples for analysis in research laboratories; scientific laboratory servicespreparation of biological samples for research purposes; scientific laboratory servicespreparation of biological samples for testing and analysis in research laboratories; product research and development; research and development for the pharmaceutical industry; research and development in the field of biotechnology; research and development in the field of diagnostic preparations; research and development in the field of immunology; research and development in the pharmaceutical and biotechnology fields; research and development of new products; research and development of new products for third parties in the field of autoimmunitycancer and rheumatoid heart disease; research and development of vaccines and medicines; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of immunology; research and development services in the field of microorganisms and cells; research and development services relating to vaccines; research in the field of autoimmune disease; research in the field of gene therapy; research in the field of genetic engineering; research in the field of inflammatory diseases; research in the field of oncology; research laboratories in the field of immunobiology; research laboratory services in the field of immunobiology; research of pharmaceuticals; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to medicine; research relating to molecular biology; research relating to pharmaceuticals; research relating to sciencescientific research; scientific investigations for medical purposes; scientific laboratory services; scientific research; scientific research and analysis in the field of immunobiology; scientific research and development; scientific research for medical purposes in the field of cancerautoimmune diseasesinfectious diseasesinflammatory diseases and allergy; scientific research for medical purposes in the area of cancerous disease; scientific research in the field of genetics and genetic engineering; scientific research relating to biology; scientific research relating to cellular therapeutics; scientific research relating to genetics; scientific research relating to immunotherapeutics; scientific research relating to prophylactic vaccines; scientific research services; scientific servicesscientific consulting and research services relating to the isolation and cultivation of human tissue and cells; scientific testing services in the field of identifying antigen targets in cancerinfectious diseaseallergyautoimmune disease and biologic drug rejectionin providing targeting immune receptors for antigen targets in said diseases
Class 44
Blood bank services; medical clinic services; therapy servicesT-cell therapy; blood banks; medical clinics; medical clinic services; medical health clinic services; medical and health care clinics; providing personalized therapy for treating cancer; providing personalized medical and health care services; provision of medical services; medical testing services relating to the diagnosis and treatment of disease; medical diagnostic testing services relating to ex vivo gene engineeringcell therapy; medical diagnostic testing services relating to cellular therapeuticscell therapy; medical diagnostic testing services relating to cell therapy; medical diagnostic testing services relating to cellular therapy; medical diagnostic testing services relating to treatment of diseases using cells; medical analysis services relating to the collectiontreatment and processing of human blood for diagnostic and treatment purposes; medical services for the treatment of cancerautoimmune disease or inflammatory disease; medical services for the treatment of conditions of the human body; medical screening services relating to oncological diseaseautoimmune disease or inflammatory disease; medical care and medical analysis services relating to patient treatment for diagnostic and treatment purposes; medical diagnostic testingmonitoring and reporting services; medical health assessment services; medical laboratory services for the analysis of samples taken from patientsmedical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical laboratory services for the analysis of blood samples taken from patients for diagnostic and treatment purposes; medical analysis services for diagnostic and treatment purposes; medical analysis services relating to the treatment of persons; medical analysis services relating to the treatment of patients; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical and health servicesmedical analysis services relating to DNAgenetics and genetic testing for medical diagnostic and treatment purposes; medical and health care services; medical services in the field of oncology; genetic testing for medical purposes
Publications
History of USPTO decisions and trademark events.
38 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/11/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/28/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/23/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/29/2021
FIMP
FINAL DISPOSITION PROCESSED
04/29/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/26/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
01/26/2021
GPNX
NOTIFICATION PROCESSED BY IB
12/12/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/25/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/10/2020
PUBO
PUBLISHED FOR OPPOSITION
11/10/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/21/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/21/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/05/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
10/05/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/05/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
10/05/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/23/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/23/2020
ALIE
ASSIGNED TO LIE
09/16/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/21/2020
GAUN
NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
08/21/2020
GAUD
NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
08/21/2020
NAUD
REPORT UNRESPONSIVE AMENDMENT - COMPLETED
08/21/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/05/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/05/2020
RFNT
REFUSAL PROCESSED BY IB
02/22/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/06/2020
RFRR
REFUSAL PROCESSED BY MPU
02/06/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/14/2020
CNRT
NON-FINAL ACTION WRITTEN
01/13/2020
MAFR
APPLICATION FILING RECEIPT MAILED
01/10/2020
DOCK
ASSIGNED TO EXAMINER
01/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/06/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/26/2019
Continuous trademark protection
Get notified about every new filing that threatens ANOCCA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.